Ahmpatinin i Bu, a new HIV-1 protease inhibitor, from Streptomyces sp. CPCC 202950.
Ming-Hua ChenShan-Shan ChangBiao DongLi-Yan YuYe-Xiang WuRen-Zhong WangWei JiangZeng-Ping GaoShu-Yi SiPublished in: RSC advances (2018)
Ahmpatinin i Bu (1) and statinin i Bu (2), two new linear peptides, a novel pyrrolidine derivative, (-)-( S )-2-[3-(6-methylheptanamido)-2-oxopyrrolidin-1-yl] acetic acid (3), and three known pepstatin derivatives (4-6) along with their corresponding methanolysis artifacts (7-9) were isolated from Streptomyces sp. CPCC 202950. Their structures were elucidated on the basis of extensive spectroscopic data using Marfey's analysis, chiral-phase HPLC, and ECD and OR calculation to determine the absolute configurations. Compound 1 contains an unusual amino acid, 4-amino-3-hydroxy-5-(4-methoxyphenyl)pentanoic acid (Ahmppa), and 3 is the first natural product with a 2-(3-amino-2-oxopyrrolidin-1-yl)acetic acid system. Compounds 1, 2, and 4-9 are HIV-1 protease inhibitors. In particular, ahmpatinin i Bu (1) exhibits significant inhibitory activity against HIV-1 protease with an IC 50 value of 1.79 nM. A preliminary structure-activity relationship is discussed.
Keyphrases
- antiretroviral therapy
- hiv positive
- hiv infected
- hiv testing
- human immunodeficiency virus
- structure activity relationship
- hepatitis c virus
- hiv aids
- men who have sex with men
- amino acid
- ms ms
- south africa
- molecular docking
- photodynamic therapy
- magnetic resonance imaging
- magnetic resonance
- tandem mass spectrometry
- neural network